†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

BUSINESS DESCRIPTIONNYCOMED MARKETSINTERNATIONAL SALESNycomed’s International Sales business segment covers a variety of markets onall continents. It works mainly with medium sized and smaller pharmaceuticalcompanies on a country by country basis. Sales of our products are influencedby the priority, focus and effort put on these by our partners. In 2000, the totalgrowth rate was 24% compared to 1999.Sales of CalciChew ® in the UK continued to grow in 2000, and CalciChew ® nowhas a market share of more than 70%. CalciChew ® also kept its position in Francewith a market share of almost 35%. Proamatine ® (Gutron ® ) showed steady growthin the USA throughout the year. Sales of TachoComb ® in Japan continued to growin 2000, (launched April 1999) and the market share at the end of the year wasapproximately 17%. Xefo ® was launched in many markets both within and outsideEurope. The product was registered in Japan in December with a plannedlaunch date of March 2001.Two important contracts were also signed in 2000. The first was an agreementmade with Nycomed Imaging governing the CalciChew ® license in China and theother was an agreement made with CeNeS Pharmaceuticals plc for the distributionrights for Xefo ® in the UK.SALES 2000PRODUCTS (DKK million) MAIN MARKET(s)CalciChew ® 166 UK, France, Spain and GermanyGutron ® 83 USA and JapanTachoComb ® 55 JapanActovegin ® 48 China and JapanXefo ® 30 Several markets (introduced 1999/2000)–23–